欧州連合 - 英語 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs.onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components.the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

欧州連合 - 英語 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - feline leukaemia virus recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.onset of immunity has been demonstrated 2 weeks after primary vaccination course.the duration of immunity is one year after the last vaccination.

欧州連合 - 英語 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 virus - immunologicals - cats - active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.onset of immunity: 4 weeks after the primary vaccination course.duration of immunity after primary vaccination: 1 year.duration of immunity after revaccination: 3 years.

欧州連合 - 英語 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - recombinant turkey herpesvirus, strain vhvt013-69, live - immunologicals for aves, domestic fowl, immunologicals - embryonated eggs; chicken - for active immunisation of chickens:to prevent mortality and to reduce clinical signs and lesions of infectious bursal disease.to reduce mortality, clinical signs and lesions of marek's disease.

欧州連合 - 英語 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - porcine circovirus type 2 orf2 protein - immunologicals for suidae - pigs - for active immunisation of pigs over the age of two weeks against porcine circovirus type 2 (pcv2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with pcv2-related disease (pcvd).in addition, vaccination has been shown to reduce pcv2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.onset of protection occurs as early as two weeks post vaccination and lasts for at least 17 weeks.

欧州連合 - 英語 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp 2242 virus / vcp1529 virus / vcp1533 virus / vcp3011 virus - immunologicals, live viral vaccines equine influenza virus - horses - active immunisation of horses of four months of age or older against equine influenza to reduce clinical signs and virus excretion after infection.

欧州連合 - 英語 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - clostridium tetani toxoid / vcp 2242 virus / vcp1529 virus / vcp1533 virus / vcp3011 virus - immunologicals for equidae, live viral and inactivated bacterial vaccines, equine influenza virus + clostridium - horses - active immunisation of horses of four months of age or older against equine influenza to reduce clinical signs and virus excretion after infection, and against tetanus to prevent mortality.

欧州連合 - 英語 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

欧州連合 - 英語 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

イギリス - 英語 - HMA (Heads of Medicines Agencies)

boehringer ingelheim vetmedica gmbh - pimobendan 5 mg - chewable tablet - dogs - pimobendane